A recent court decision has ostensibly made if possible for generic-drug companies to manufacture their own versions of the fish oil pill Lovaza. How does this news affect shareholders of GlaxoSmtihKline (GSK 0.19%), the company that sells the drug in the U.S., and how can this decision affect rivals like struggling biotech company Amarin (AMRN -1.65%)

Analysts David Williamson and Max Macaluso discuss these topics in the following video segment from The Motley Fool's health-care show Market Checkup.